C4 Therapeutics CCCC 深 沪
等待开盘 10-01 09:30:00 美东时间
3.33
+0.200
+6.39%
华盛通- 最 高3.37
- 今 开3.16
- 成交量 260.92万股
- 最 低 3.13
- 昨 收 3.13
- 总市值 4.10亿
- 52周最高 5.17
- 市盈率 静 --
- 换手率 2.12%
- 52周最低 1.6901
- 委 比 27.86%
- 总股本 1.23亿
- 历史最高 51.21
- 量 比 0.94
- 振 幅 7.67%
- 历史最低 1.06
- 每 手 1
- 风险率 0.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多C4 Therapeutics Presents New Biomarker Data From Phase 1 Clinical Trial Of Cemsidomide In Combination With Dexamethasone In Patients With RRMM At 23rd IMS Annual Meeting
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of Action Biomarker Data from First Two Patients in Phase 1b Trial of Cemsidomide with Elranatamab Reinforce Cemsidomide’s Ability to D...
09-25 19:02
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Cemsidomide, an investigational oral cereblon-modulating protein degrader, demonstrated robust T-cell activation and NK cell reprogramming in Phase 1 trials for relapsed/refractory multiple myeloma (RRMM). Early Phase 1b data with elranatamab showed T-cell expansion and reduced exhaustion, supporting its potential as an immune therapy partner. The 75 µg dose was deemed safe, advancing the trial to higher doses, with full Phase 1b results expected...
09-25 11:00
C4 Therapeutics To Present New Biomarker Data On Immunomodulatory Effects Of Cemsidomide In Combination With Dexamethasone From Phase 1 Trial For RRMM At IMS Annual Meeting
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 trial for...
09-03 19:10
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
C4 Therapeutics announced new biomarker data on cemsidomide's immunomodulatory effects in combination with dexamethasone for relapsed/refractory multiple myeloma (RRMM) from its Phase 1 trial. The data, to be presented at the 23rd IMS Annual Meeting in Glasgow, Scotland, highlight immune effects on T and NK cells, supporting cemsidomide's potential as a combination therapy for immune-based treatments. Cemsidomide is a next-generation MonoDAC® deg...
09-03 11:00
C4 Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
C4 Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
08-12 00:58
C4 Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate, Sales $6.641M Beat $4.000M Estimate
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 51.35 percent increase over losses of $(0.37) per share from the same period last year. The company reported quarterly sales of $6.641 million...
08-11 19:34
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
C4 Therapeutics reported progress on its cemsidomide program, including Phase 2 MOMENTUM trial and Phase 1b trials in combination with elranatamab and standard of care therapies, with data expected in 2027. The company highlighted cemsidomide's differentiated safety and anti-myeloma activity in heavily pretreated patients, supporting its potential as a best-in-class therapy. Financially, Q2 2026 revenue increased to $6.6 million due to the Roche ...
08-11 11:00
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics, Inc. (Nasdaq: CCCC) announced the grant of non-qualified stock options to purchase 162,880 shares of its common stock to a new employee on August 10, 2026. The options, priced at the closing price on the grant date, vest over four years with 25% after the first year and the rest in monthly installments. C4T is a clinical-stage biopharmaceutical company advancing targeted protein degradation science to develop innovative medicines...
08-10 20:01
C4 Therapeutics To Present Further Analysis From Fully Enrolled Phase 1 Trial Of Cemsidomide In Combination With Dexamethasone For Treatment Of RRMM At EHA 2026 Congress
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status Cemsidomide Was Well Tolerated With Minimal Discontinuations and Dose Reductions Related to Safety or Tolerability Dat...
06-11 19:12
